Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

被引:435
作者
Gong, Q
Ou, QL
Ye, SM
Lee, WP
Cornelius, J
Diehl, L
Lin, WY
Hu, ZL
Lu, YM
Chen, YM
Wu, Y
Meng, YG
Gribling, P
Lin, ZH
Nguyen, K
Tran, T
Zhang, YF
Rosen, H
Martin, F
Chan, AC
机构
[1] Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Antibody Engn, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Assay & Automated Technol, San Francisco, CA 94080 USA
[4] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA
[5] Scripps Res Inst, Inst Childhood & Neglected Dis, Dept Immunol, La Jolla, CA 92037 USA
关键词
D O I
10.4049/jimmunol.174.2.817
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
B cell immunotherapy has emerged as a mainstay in the treatment of lymphomas and autoimmume diseases. Although the microenvironment has recently been demonstrated to play critical roles in B cell homeostasis, its contribution to immunotherapy is unknown. To analyze the in vivo factors that regulate mechanisms involved in B cell immunotherapy, we used a murine model for human CD20 (hCD20) expression in which treatment of hCD20(+) mice with anti-hCD20 mAbs mimics B cell depletion observed in humans. We demonstrate in this study that factors derived from the microenvironment, including signals from the B cell-activating factor belonging to the TNF family/BLyS survival factor, integrin-regulated homeastasis. and circulatory dynamics of B cells define distinct in vivo mechanism(s) and sensitivities of cells in anti-hCD20 mAb-directed therapies. These findings provide new insights into the mechanisms of immunotherapy and define new opportunities in the treatment of cancers and autoimmune diseases.
引用
收藏
页码:817 / 826
页数:10
相关论文
共 39 条
  • [1] The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    Anolik, JH
    Campbell, D
    Felgar, RE
    Young, F
    Sanz, I
    Rosenblatt, J
    Looney, RJ
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (02): : 455 - 459
  • [2] Variation in gene expression patterns in follicular lymphoma and the response to rituximab
    Bohen, SP
    Troyanskaya, OG
    Alter, O
    Warnke, R
    Botstein, D
    Brown, PO
    Levy, R
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) : 1926 - 1930
  • [3] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
    Cartron, G
    Dacheux, L
    Salles, G
    Solal-Celigny, P
    Bardos, P
    Colombat, P
    Watier, H
    [J]. BLOOD, 2002, 99 (03) : 754 - 758
  • [4] Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
    Clynes, RA
    Towers, TL
    Presta, LG
    Ravetch, JV
    [J]. NATURE MEDICINE, 2000, 6 (04) : 443 - 446
  • [5] Cyster JG, 2002, ADV EXP MED BIOL, V512, P35
  • [6] INVIVO ABROGATION OF SERUM C3 AND C5 BY ADMINISTRATION OF COBRA VENOM FACTOR AND HETEROLOGOUS ANTI-C3
    DRAKE, WP
    POKORNEY, DR
    MARDINEY, MR
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1974, 6 (1-2) : 61 - 72
  • [7] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    Edwards, JCW
    Szczepanski, L
    Szechinski, J
    Filipowicz-Sosnowska, A
    Emery, P
    Close, DR
    Stevens, RM
    Shaw, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) : 2572 - 2581
  • [8] FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
    Farag, SS
    Flinn, IW
    Modali, R
    Lehman, TA
    Young, D
    Byrd, JC
    [J]. BLOOD, 2004, 103 (04) : 1472 - 1474
  • [9] CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
    Golay, J
    Lazzari, M
    Facchinetti, V
    Bernasconi, S
    Borleri, G
    Barbui, T
    Rambaldi, A
    Introna, M
    [J]. BLOOD, 2001, 98 (12) : 3383 - 3389
  • [10] GOLDSTEIN G, 1985, NEW ENGL J MED, V313, P337